Shorter All-oral Bedaquiline-containing MDR-TB Regimen : The Backgrounds & Implementations

The continuing spread of Multidrug-Resistant Tuberculosis (MDR-TB), which is defined as TB that shows resistance to both isoniazid and rifampicin, become one the most urgent difficult challenges in control. In Indonesia, estimated total DR-TB case incidence 24,000 or 8.8/100,000 population (2.4% new patients). first-ever MDR-TB treatment guideline published by WHO required a long duration (up 20–24 months) contained toxic second-line drugs with less effective & unfavorable outcomes. About ten years ago, short regimen lasting nine instead 20 months, called “Bangladesh regimen”, revolutionized treatment. advent rapid molecular diagnostic tests, discoveries repurposed drugs, promising results based on trials meta-analysis had prompted update its guidelines. Notably, such bedaquiline clofazimine are now strongly recommended for MDR-TB. At same time, older injectables have been downgraded due poor effectiveness side-effect profiles. 2019, programmatic data from shorter all-oral bedaquiline-containing implemented routinely South Africa, revised recommendations use standardized regimen. Based analysis, affirmed conditional recommendation MDR -TB be offered option patients who satisfy eligibility criteria. implementation this expected improve management worldwide.